Today, MDNA Life Sciences announces that it is to launch the world’s first blood test for endometriosis, able to detect the disease in up to 9 out of 10 cases. Results will be available in a matter of days after the test is carried out, enabling doctors to make earlier decisions on diagnosis and treatment.
Continue reading “World’s first blood test for Endometriosis can detect up to 9 out of 10 cases”
Our announcement of the forthcoming UK launch of our blood test for the detection of Endometriosis has captured the attention of journalists and health corespondents in broadcast, print and the digital space around the World.
MDNA Life Sciences Inc. (MDNA) announced today that the results of a recent study have been published in the journal, Biomarkers in Medicine (Biomarkers In Medicine). The study reports the evaluation of mitochondrial DNA (mtDNA) deletions detected in blood plasma as promising biomarkers for the detection of endometriosis. Based on the performance reported in the publication, biomarkers of the mitochondrial genome, discovered through MDNAs proprietary Mitomic Technology™ platform, offer ground-breaking potential for a non-invasive test for endometriosis.
MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today that it has appointed Orion Diagnostica Oy (Orion) as the exclusive distributor for the Mitomic® Prostate Test (MPT™) in Germany, Denmark, Finland, Sweden, Norway, Poland, Czech Republic, Slovakia, and Hungary.
WEST PALM BEACH, FL / ACCESSWIRE / October 9, 2018 / MDNA Life Sciences Inc. (MDNA), the molecular diagnostics company revolutionizing the development of liquid biopsy biomarkers based on the mitochondrial genome, announced today that the Mitomic® Prostate Test (MPT™) Real-Time PCR Kit is now CE marked and being made available worldwide.